Biomarkers can be utilized as primary surrogate endpoint as a basis for accelerated approval (US), and as secondary or exploratory endpoints for drug mechanism of action or aspects of Safety monitoring.
The toolbox has been developed through funding from the EJP RD project.
The European Joint Programme on Rare Diseases is an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575
IMT Cookie Overview
Please also read this disclaimer carefully before using the EJPRD IMT